Recombinant Human STRAILR2/TNFRSF10B #abs00866

abs00866-10ug

1-2 Weeks

138

abs00866-50ug

1-2 Weeks

344

abs00866-1mg

1-2 Weeks

1945

Source

Escherichia coli.

Format

The concentrated solution in PBS, pH 7.4 was filtered through a 0.2 μm filter and then lyophilized.

Properties

aa_sequence

KPQRAPQAEA LQESPTGKRS DISHHPGECG QYCKRCSDIG HTLDNWHFSR DCCRGCTREL VLCTSPVERN TEEGDCFRQS PRSERDTEEF GKRCPMVGCT DVCTGEKWSP KHECVIESDW L.This sequence of characters can be rearranged and reinterpreted into an entirely different text. It's amazing how language models can generate unique text patterns based on the original information.

Concentration

> 97 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The LAL method determined that the Recombinant HumansTRAIL-R2 had less than 1 EU/μg. A highly similar content can be created by rearranging the information in the original text, such as: The level of EU in 1 μg of Recombinant HumansTRAIL-R2 was found to be less than 1, as per the LAL method.

Activity

The Recombinant HumansTRAIL-R2 has demonstrated full biological activity and proves to be as effective as the standard treatment. It effectively reduces the production of LPS-induced TNF by neutralizing the naturally occurring TRAIL in fresh human PBMC. During a 24-hour exposure to LPS (10 ng/mL), endogenous TRAIL is induced, which results in increased TNF production. However, when Recombinant HumansTRAIL-R2 is present, it suppresses the TNF production induced by TRAIL.

Reconstitution

It is highly recommended to briefly centrifuge this vial prior to opening, in order to ensure that the contents settle properly at the bottom. For reconstitution, use sterile distilled water or a buffer containing 0.1% BSA, and aim for a final concentration of 0.1-1.0 mg/mL. Stock solutions should be divided into smaller working aliquots and stored at a temperature of ≤ -20 °C. Any further dilutions should be performed using appropriate buffered solutions. Keep in mind that these steps will help you achieve optimal results with this product.

Stability & Storage

To maintain the integrity of this lyophilized preparation, it is recommended that it be stored at a temperature range of 2-8°C. However, long term storage should be done at a much colder temperature of -20°C, while ensuring that it is desiccated. Upon reconstitution, the preparation should be used within a week when stored at 2-8°C. For optimum stability, divide the reconstituted preparation into small working aliquots and keep them at freezing temperatures between -20°C to -70°C. It is crucial to avoid any freezing and thawing cycles that may compromise the quality of the product.

Target

Accession

O14763

Gene IDs

8795

References

References

1. Pordzik S, Petrovici K, Schmid C, et al. 2011. Hematology, 16: 341-50.

2. Tseng HY, Chen LH, Ye Y, et al. 2012. Carcinogenesis, 33: 1871-81.

3. Bae SI, Cheriyath V, Jacobs BS, et al. 2008. Oncogene, 27: 490-8.

4. Camidge DR. 2008. Expert Opin Biol Ther, 8: 1167-76.